$ Value
$0
Shares
15,824
Price
$0
Filed
May 2
Insider
Name
Richard Ronald
Title
—
CIK
0001380177
Roles
Transaction Details
Transaction Date
2025-04-30
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
41,572
Footnotes
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. | Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. | The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Filing Info
Richard Ronald's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-12-05 | EBS | ▼ | $86K |
| 2025-12-05 | EBS | M | $129K |
| 2025-12-05 | EBS | F | $129K |
| 2025-12-05 | EBS | ▼ | $177K |
| 2025-12-05 | EBS | M | $0 |
| 2025-04-30 | EBS | A | $0 |
| 2025-04-30 | EBS | A | $0 |
Other Insiders at EBS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| FOWLER JOHN D JR | — | — | 2026-03-03 |
|
LINDAHL RICHARD S
EVP, Chief Financial Officer
|
— | — | 2026-03-05 |
|
PAPA JOSEPH C
President and CEO
|
— | — | 2026-03-05 |
|
Glessner Coleen
EVP, Quality & Ethics, and CPL
|
— | — | 2026-03-05 |
|
Williams Paul Anthony
SVP, Products Business
|
— | $34K | 2026-04-01 |
|
Hartzel William
SVP, Bioservices
|
— | — | 2026-03-05 |
|
Perl Jessica
SVP, General Counsel, Corp Sec
|
— | — | 2026-03-05 |
|
Lowry Simon C
SVP, R&D, CMO
|
— | — | 2026-03-05 |